- Oral presentation
- Open Access
Human papillomavirus prevalence in invasive cervical carcinoma by HIV Status
© De Vuyst et al; licensee BioMed Central Ltd. 2012
- Published: 19 April 2012
- Prevalence Ratio
- Squamous Cell Cancer
- Borderline Statistical Significance
- Freeze Biopsy
- Invasive Cervical Carcinoma
Data on the prevalence of human papillomavirus (HPV) types in invasive cervical carcinoma (ICC) in women with HIV are scarce but are essential to elucidate the influence of immunity on the carcinogenicity of different HPV types, and the potential impact of prophylactic HPV vaccines in populations with high HIV prevalence.
To compare the prevalence of HPV types in ICC by HIV status.
From 2007 to 2009, a multicentre case-case study was conducted at two referral hospitals in Nairobi, Kenya, and in Durban, South Africa. Women over 18 years of age presenting with ICC were recruited, and frozen biopsies were obtained and tested for HPV DNA using GP5+/6+-PCR methodology. The present analysis was limited to the 235 squamous cell cancers (SCC) detected.
Overall, our data suggest that current prophylactic HPV vaccines against HPV16 and 18 may prevent similar proportions of cervical SCC in HIV-positive as in HIV-negative women provided that vaccine-related protection is sustained after HIV infection.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.